- Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers 30 April 2021 Björn F Vahsen
- Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells 14 April 2021 Peter A C Wing
- The antigenic anatomy of SARS-CoV-2 receptor binding domain 23 March 2021 Wanwisa Dejnirattisai
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera 21 March 2021 Piyada Supasa
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera 17 March 2021 Daming Zhou
- In vitro Quantitative Imaging Assay for Phagocytosis of Dead Neuroblastoma Cells by iPSC-Macrophages 1 March 2021 Hazel Hall-Roberts
- Breadth and function of antibody response to acute SARS-CoV-2 infection in humans 26 February 2021 Kuan-Ying A Huang
- Molecular and electrophysiological features of spinocerebellar ataxia type seven in induced pluripotent stem cells 24 February 2021 Richard J Burman
- Alzheimer's Risk Gene TREM2 Determines Functional Properties of New Type of Human iPSC-Derived Microglia 22 February 2021 Marvin Reich
- Genome-wide CRISPR/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages 20 February 2021 Elena Navarro-Guerrero
Postdoctoral Research Assistant | ARUK ODDI | firstname.lastname@example.org
Dr Hazel Hall-Roberts (née Roberts) joined the lab in 2016, to research the role of microglia in Alzheimer’s disease. Microglia are immune cells that maintain a healthy brain environment by clearing up pathogens and ‘self’-made debris through a process called phagocytosis (‘cell eating’). Pathogens provoke a fuIl immune response, but ‘self’ debris usually does not. In an Alzheimer’s brain, microglial phagocytosis is impaired, and the microglia enter a state of chronic inflammation, in the absence of pathogens. Hazel’s current project is jointly supervised by Dr Sally Cowley, and Dr Elena Di Daniel at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Their main goal is to develop assays and tools for investigating microglial function in the context of Alzheimer’s disease, particularly their ability to clear neuronal debris via phagocytosis, using iPSC-derived macrophages as a cell model.
Hazel graduated from the University of Bristol in 2012 with a BSc in Biochemistry with Year in Industry, having spent a year working at GlaxoSmithKline Stevenage. At GlaxoSmithKline her research project looked at epigenetic proteins involved in the acute inflammation response of macrophages. This was followed by a PhD at the University of Bath (2012-16) with Professor David Brown, conducting research on α-synuclein, a protein that disrupts cell function in Parkinson’s disease, and how it promotes neuronal cell secretion of β-amyloid, a peptide that plays a key role in Alzheimer’s disease.